




Instance: composition-en-2128cb95d4d26d25d7fa2c3944c0ae92
InstanceOf: CompositionUvEpi
Title: "Composition for ranexa Package Leaflet"
Description:  "Composition for ranexa Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/08/462/001  60 tablets in blister pack"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp2128cb95d4d26d25d7fa2c3944c0ae92)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - ranexa"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  
  </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol type="1">
<li>What Ranexa is and what it is used for</li>
<li>What you need to know before you take Ranexa</li>
<li>How to take Ranexa</li>
<li>Possible side effects</li>
<li>How to store Ranexa</li>
<li>Contents of the pack and other information</li>
</ol>
 </div>"""   
          

* section[=].section[+]
  * title =  "1. What ranexa is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What ranexa is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Ranexa is a medicine used in combination with other medicines to
treat angina pectoris, which is a chest pain or discomfort that you feel
anywhere along the upper part of your body between your neck and upper
abdomen, often brought on by exercise or too much activity.</p>
<p>You must talk to a doctor if you do not feel better or if you feel
worse.</p>
 </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take ranexa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take ranexa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Ranexa</p>
<ul>
<li>if you are allergic to ranolazine or any of the other ingredients of
this medicine listed in section 6 of this leaflet.</li>
<li>if you have severe kidney problems.</li>
<li>if you have moderate or severe liver problems.</li>
<li>if you are using certain medicines to treat bacterial infections
(clarithromycin, telithromycin), fungal infections (itraconazole,
ketoconazole, voriconazol, posaconazol), HIV infection (protease
inhibitors), depression (nefazodone) or heart rhythm disorders (e.g.
quinidine, dofetilide, or sotalol).</li>
</ul>
<p>Warning and precautions Talk to your doctor before taking Ranexa:</p>
<ul>
<li>if you have mild or moderate kidney problems.</li>
<li>if you have mild liver problems.</li>
<li>if you have ever had an abnormal electrocardiogram (ECG).</li>
<li>if you are elderly.</li>
<li>if you have low weight (60 kg or less).</li>
<li>if you have heart failure. Your doctor may decide to give you a
lower dose or take other precautions if any of these apply to you.</li>
</ul>
<p>Using other medicines and Ranexa Do not use the following medicines
if you take Ranexa:</p>
<ul>
<li>certain medicines to treat bacterial infections (clarithromycin,
telithromycin), fungal infections (itraconazole, ketoconazole,
voriconazole, posaconazole), HIV infection (protease inhibitors),
depression (nefazodone), or heart rhythm disorders (e.g. quinidine,
dofetilide, or sotalol).</li>
</ul>
<p>Tell your doctor or pharmacist before you take Ranexa if you use:</p>
<ul>
<li>certain medicines to treat a bacterial infection (erythromycin), or
a fungal infection (fluconazole), a medicine used to prevent rejection
of a transplanted organ (ciclosporin), or if you are taking some heart
tablets such as diltiazem or verapamil. These medicines may cause an
increase in the number of side effects, such as dizziness, nausea, or
vomiting, which are possible side effects of Ranexa (see section 4).
Your doctor may decide to give you a lower dose.</li>
<li>medicines to treat epilepsy or another neurologic disorder (e.g.
phenytoin, carbamazepine, or phenobarbital); are taking rifampicin for
an infection (e.g. tuberculosis); or are taking the herbal remedy St.
John's Wort, as these medicines may cause Ranexa to be less
effective.</li>
<li>heart medicines containing digoxin or metoprolol, as your doctor may
want to change the dose of this medicine whilst you are taking
Ranexa.</li>
<li>certain medicines to treat allergies (e.g. terfenadine, astemizole,
mizolastine), heart rhythm disorders (e.g. disopyramide, procainamide),
and depression (e.g. imipramine, doxepin, amitriptyline), as these
medicines may affect your ECG.</li>
<li>certain medicines to treat depression (bupropion), psychosis, HIV
infection (efavirenz), or cancer (cyclophosphamide).</li>
<li>certain medicines to treat high levels of cholesterol in the blood
(e.g. simvastatin, lovastatin, atorvastatin). These medicines may cause
muscle pain and muscle injury. Your doctor may decide to change the dose
of this medicine while you are taking Ranexa.</li>
<li>certain medicines used to prevent transplanted organ rejection (e.g.
tacrolimus, ciclosporin, sirolimus, everolimus) as your doctor may
decide to change the dose of this medicine while you are taking
Ranexa.</li>
</ul>
<p>Tell your doctor or pharmacist if you are using or have recently used
or might use any other medicines.</p>
<p>Ranexa with food and drink Ranexa can be taken with or without food.
While being treated with Ranexa, you should not drink grapefruit
juice.</p>
<p>Pregnancy You should not take Ranexa if you are pregnant unless your
doctor has advised you to do so.</p>
<p>Breast-feeding You should not take Ranexa if you are breast-feeding.
Ask your doctor for advice if you are breast- feeding.</p>
<p>If you are pregnant or breast-feeding, think you may be pregnant or
are planning to have a baby, ask your doctor for advice before taking
this medicine.</p>
<p>Driving and using machines No studies on the effects of Ranexa on the
ability to drive and use machines have been performed. Ask your doctor
for advice about driving or using machines.</p>
<p>Ranexa may cause side effects such as dizziness (common), blurred
vision (uncommon), confusional state (uncommon), hallucination
(uncommon), double vision (uncommon), coordination problems (rare), that
may affect your ability to drive or use machines. If you experience
these symptoms, do not drive or operate machinery until they have
resolved completely.</p>
<p>Ranexa 750 mg prolonged-release tablets contain the azo colouring
agent E102. This colouring agent- may cause allergic reactions.</p>
<p>Ranexa 750 mg prolonged-release tablets contain lactose monohydrate.
If you have been told by your doctor that you have an intolerance to
some sugars, contact your doctor before taking this medicinal
product.</p>
<p>This medicine contains less than 1 mmol sodium (23 mg) per
prolonged-release tablet, that is to say essentially sodium-free .</p>
 </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take ranexa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take ranexa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you to.
Check with your doctor or pharmacist if you are not sure.</p>
<p>Always swallow the tablets whole with water. Do not crush, suck, or
chew the tablets or break them in half, as this might affect the way the
medicine is released from the tablets into your body.</p>
<p>The starting dose for adults is one 375 mg tablet twice a day. After
2 4 weeks, your doctor may increase the dose to get the right effect.
The maximum dose of Ranexa is 750 mg twice a day.</p>
<p>It is important that you tell your doctor if you get side effects
such as dizziness or feeling or being sick. Your doctor may lower your
dose or, if this is not sufficient, stop treatment with Ranexa.</p>
<p>Use in children and adolescents Children and adolescents under 18
years old should not take Ranexa.</p>
<p>If you take more Ranexa than you should If you accidentally take too
many Ranexa tablets or take a higher dose than recommended by your
doctor, it is important that you tell your doctor at once. If you cannot
contact your doctor, go to the nearest accident and emergency
department. Take along any tablets that are left, including the
container and the carton, so that the hospital staff can easily tell
what you have taken.</p>
<p>If you forget to take Ranexa If you forget to take a dose, take it as
soon as you remember unless it is nearly time (less than 6 hours) to
take your next dose. Do not take a double dose to make up for a
forgotten dose.</p>
 </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although
not everybody gets them.</p>
<p>You should stop taking Ranexa and see your doctor immediately if you
experience the following symptoms of angioedema, which is a rare
condition but can be severe:</p>
<ul>
<li>swollen face, tongue, or throat</li>
<li>difficulty swallowing</li>
<li>hives or difficulty breathing</li>
</ul>
<p>Tell your doctor if you experience common side effects such as
dizziness or feeling sick or vomiting.<br />
Your doctor may lower your dose or stop treatment with Ranexa.</p>
<p>Other side effects you may experience include the following:</p>
<p>Common side effects (occur in 1 to 10 users in 100) are:<br />
Constipation Dizziness Headache Feeling sick, vomiting Feeling weak</p>
<p>Uncommon side effects (occur in 1 to 10 users in 1,000) are:<br />
Altered sensation Anxiety, difficulty sleeping, confusional state,
hallucination Blurred vision, visual disturbance Changes in sensation
(touch or taste), tremor, feeling tired or sluggish, sleepiness or
drowsiness, faint or fainting, dizziness upon standing<br />
Dark urine, blood in urine, difficulty urinating Dehydration Difficulty
breathing, cough, nose bleed Double vision Excessive sweating, itching
Feeling swollen or bloated Hot flushes, low blood pressure<br />
Increases in a substance called creatinine or increases in urea in your
blood, increase in blood platelets or white blood cells, changes in ECG
heart tracing Joint swelling, pain in extremity Loss of appetite and/or
weight loss Muscle cramp, muscle weakness Ringing in the ears and/or
feeling a spinning sensation Stomach pain or discomfort, indigestion,
dry mouth, or wind</p>
<p>Rare side effects (occur in 1 to 10 users in 10,000) are: A lack of
ability to urinate Abnormal laboratory values for liver<br />
Acute kidney failure Change in sense of smell, numbness in mouth or
lips, impaired hearing Cold sweat, rash Coordination problems Decrease
in blood pressure upon standing Decreased or loss of consciousness
Disorientation Feeling of coldness in hands and legs Hives, allergic
skin reaction Impotence Inability to walk due to imbalance Inflammation
of pancreas or intestine<br />
Loss of memory Throat tightness Low level of sodium in the blood
(hyponatremia) which can cause tiredness and confusion, muscle
twitching, cramps, and coma.</p>
<p>Not known side effects (frequency cannot be estimated from the
available data) are: Myoclonus</p>
<p>Reporting of side effects</p>
<p>If you get any any side effects talk to your doctor or pharmacist.
This include any possible side effects not listed in this leaflet. You
can also report side effects directly via the national reporting system
listed in Appendix V. By reporting side effects you can help provide
more information on the safety of this medicine.</p>
 </div>"""      
        
* section[=].section[+]
  * title = "5. How to store ranexa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store ranexa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.</p>
<p>Do not use this medicine after the expiry date which is stated on
each blister strip of tablets and on the outside of the carton and
bottle after EXP.</p>
<p>This medicinal product does not require any special storage
conditions.</p>
<p>Do not throw away any medicines via wastewater or household waste.
Ask your pharmacist how to throw away medicines you no longer use. These
measures will help protect the environment.</p>
 </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Ranexa contains The active substance in Ranexa is ranolazine.
Each tablet contains 375 mg, 500 mg, or 750 mg ranolazine.</p>
<p>The other ingredients are: hypromellose, magnesium stearate,
methacrylic acid-ethyl acrylate copolymer, microcrystalline cellulose,
sodium hydroxide, titanium dioxide and carnauba wax.</p>
<p>Depending on the tablet strength, the tablet coatings also contain:
375 mg tablet: macrogol, polysorbate 80, Blue #2/Indigo Carmine
Aluminium Lake (E132) 500 mg tablet: macrogol, talc, polyvinyl
alcohol-part hydrolyzed, iron oxide yellow (E172), iron oxide red (E172)
750 mg tablet: glycerol triacetate, lactose monohydrate, Blue
#1/Brilliant Blue FCF Aluminium Lake (E133) and Yellow #5/Tartrazine
Aluminium Lake (E102)</p>
<p>What Ranexa looks like and contents of the pack Ranexa
prolonged-release tablets are oval shaped tablets. The 375 mg tablets
are pale blue and are engraved with 375 on one side. The 500 mg tablets
are light orange and are engraved with 500 on one side. The 750 mg
tablets are pale green and are engraved with 750 on one side.</p>
<p>Ranexa is supplied in cartons containing 30, 60, or 100 tablets in
blister strips or 60 tablets in plastic bottles. Not all pack-sizes may
be marketed.</p>
<p>Marketing Authorisation Holder Menarini International Operations
Luxembourg S.A. 1, Avenue de la Gare, L-1611 Luxembourg, Luxembourg</p>
<p>Manufacturer</p>
<p>Menarini - Von Heyden GmbH Leipziger Stra e 7-01097 Dresden<br />
Germany</p>
<p>or</p>
<p>Berlin-Chemie AG Glienicker Weg 12489 Berlin Germany</p>
<p>For any information about this medicinal product, please contact the
local representative of the Marketing Authorisation Holder.</p>
<p>Belgi /Belgique/Belgien Menarini Benelux NV/SA T l/Tel: + 32 (0)2 721
4Lietuva UAB BERLIN-CHEMIE MENARINI BALTIC<br />
Tel: +370 52 691</p>
<ul>
<li>/ .</li>
</ul>
<p>.: +359 2 454 0Luxembourg/Luxemburg Menarini Benelux NV/SA T l/Tel: +
32 (0)2 721 4 esk republika Berlin-Chemie/A.Menarini Ceska republika
s.r.o. Tel: +420 267 199 Magyarorsz g Berlin-Chemie/A. Menarini Kft.
Tel.: +36 17997Danmark Menarini International Operations Luxembourg S.A.
Tel: +352 264Malta Menarini International Operations Luxembourg S.A.
Tel: +352 264Deutschland Berlin-Chemie AG Tel: +49 (0) 30 67Nederland
Menarini Benelux NV/SA Tel: +32 (0)2 721 4Eesti O Berlin-Chemie Menarini
Eesti Tel: +372 667 5Norge Menarini International Operations Luxembourg
S.A. Tlf: +352 264<br />
MENARINI HELLAS AE : +30 210 8316111- sterreich A. Menarini Pharma GmbH.
Tel: +43 1 879 95 85-0</p>
<p>Espa a Laboratorios Menarini S.A. Tel: +34-93 462 88 Polska
Berlin-Chemie/Menarini Polska Sp. z o.o. Tel.: +48 22 566 21 France
MENARINI France T l: +33 (0)1 45 60 77 Portugal A. Menarini Portugal
Farmac utica, S.A. Tel: +351 210 935 Hrvatska Berlin-Chemie Menarini
Hrvatska d.o.o. Tel: + 385 1 4821 Rom nia Berlin-Chemie A. Menarini
S.R.L. Tel: +40 211 232 34 Ireland A. Menarini Pharmaceuticals Ltd Tel:
+353 1 284 6Slovenija Berlin-Chemie / A. Menarini Distribution Ljubljana
d.o.o. Tel: +386 01 300 2 sland Menarini International Operations
Luxembourg S.A. S mi: +352 264Slovensk republika Berlin-Chemie / A.
Menarini Distribution Slovakia s.r.o Tel: +421 2 544 30 Italia A.
Menarini Industrie Farmaceutiche Riunite s.r.l. Tel: +39-055
56Suomi/Finland Berlin-Chemie/A.Menarini Suomi OY Puh/Tel: +358 403
000<br />
MENARINI HELLAS AE : +30 210 8316111-Sverige Menarini International
Operations Luxembourg S.A. Tel: +352 264Latvija SIA
Berlin-Chemie/Menarini Baltic Tel: +371 67103United Kingdom (Northern
Ireland) A. Menarini Farmaceutica Internazionale S.R.L. Tel: +44 (0)1628
856This leaflet was last revised in</p>
<p>Detailed information on this medicine is available on the European
Medicines Agency web site <a
href="http://www.ema.europa.eu">http://www.ema.europa.eu</a>.</p>
 </div>"""      



Instance: composition-da-2128cb95d4d26d25d7fa2c3944c0ae92
InstanceOf: CompositionUvEpi
Title: "Composition for ranexa Package Leaflet"
Description:  "Composition for ranexa Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/08/462/001  60 tablets in blister pack"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp2128cb95d4d26d25d7fa2c3944c0ae92)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - ranexa"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. INDLÆGSSEDDEL"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. INDLÆGSSEDDEL"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Indlægsseddel: Information til brugeren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Indlægsseddel: Information til brugeren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  
  </div>"""   



* section[=].section[+]
  * title = "Oversigt over indlægssedlen"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Oversigt over indlægssedlen"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen:</p>
<ol type="1">
<li>Virkning og anvendelse</li>
<li>Det skal du vide, før du begynder at tage Ranexa</li>
<li>Sådan skal du tage Ranexa</li>
<li>Bivirkninger</li>
<li>Opbevaring</li>
<li>Pakningsstørrelser og yderligere oplysninger</li>
</ol>
 </div>"""   
          

* section[=].section[+]
  * title =  "1. Virkning og anvendelse"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. Virkning og anvendelse"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Ranexa er en medicin, der bruges i kombination med anden medicin til
behandling af angina pectoris, som er brystsmerter eller ubehag et
hvilket som helst sted i den øverste del af kroppen mellem halsen og
maven, og som ofte udløses af træning eller for megen aktivitet.</p>
<p>Kontakt lægen, hvis du får det værre, eller hvis du ikke får det
bedre.</p>
 </div>"""   
          

             
* section[=].section[+]
  * title = "2. Det skal du vide, før du begynder at tage  ranexa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. Det skal du vide, før du begynder at tage  ranexa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Ranexa</p>
<ul>
<li><p>hvis du er allergisk over for ranolazin eller et af de øvrige
indholdsstoffer i Ranexa angivet i punkt 6. - hvis du har svære
nyreproblemer.</p></li>
<li><p>hvis du har moderate til svære leverproblemer.</p></li>
<li><p>hvis du tager visse typer medicin mod bakterielle infektioner
(clarithromycin, telithromycin), svampeinfektioner (itraconazol,
ketoconazol, voriconazol, posaconazol), hiv-infektion (proteasehæmmere),
depression (nefazodon) eller forstyrrelser i hjerterytmen (f.eks.
quinidin, dofetilid eller sotalol). . Advarsler og forsigtighedsregler
Kontakt lægen, før du tager Ranexa:</p></li>
<li><p>hvis du har lette til moderate nyreproblemer.</p></li>
<li><p>hvis du har lette leverproblemer.</p></li>
<li><p>hvis du tidligere har haft et unormalt elektrokardiogram
(EKG).</p></li>
<li><p>hvis du er ældre.</p></li>
<li><p>hvis din kropsvægt er lav (60 kg eller derunder).</p></li>
<li><p>hvis du lider af hjertesvigt.</p></li>
</ul>
<p>Hvis noget af det ovenstående gælder for dig, er det muligt, at din
læge nedsætter din dosis eller ændrer din behandling på anden vis.</p>
<p>Brug af anden medicin sammen med Ranexa Brug ikke følgende medicin,
hvis du tager Ranexa:</p>
<ul>
<li>visse former for medicin, der bruges til behandling af bakterielle
infektioner (clarithromycin, telithromycin), svampeinfektioner
(itraconazol, ketoconazol, voriconazol, posaconazol), hiv- infektion
(proteasehæmmere), depression (nefazodon) eller forstyrrelser i
hjerterytmen (f.eks. quinidin, dofetilid eller sotalol).</li>
</ul>
<p>Fortæl det til din læge eller på apoteket, før du tager Ranexa, hvis
du tager:</p>
<ul>
<li>visse former for medicin, der bruges til behandling af bakterielle
infektioner (erythromycin) eller svampeinfektioner (fluconazol),
medicin, der skal forebygge afstødning af et transplanteret organ
(ciclosporin), eller hvis du tager visse hjertetabletter såsom diltiazem
eller verapamil. Disse midler vil kunne medføre, at du får flere
bivirkninger såsom svimmelhed, kvalme eller opkastning, som er mulige
bivirkninger ved Ranexa (se pkt. 4). Din læge kan beslutte at nedsætte
din dosis.</li>
<li>medicin, der bruges til behandling af epilepsi eller andre
neurologiske forstyrrelser (f.eks. phenytoin, carbamazepin eller
phenobarbital), rifampicin til infektionsbehandling (f.eks. tuberkulose)
eller naturlægemidlet prikbladet perikon, da disse former for medicin
kan nedsætte virkningen af Ranexa.</li>
<li>hjertemedicin, der indeholder digoxin eller metoprolol, da din læge
muligvis vil ønske at ændre doseringen af denne medicin, mens du tager
Ranexa.</li>
<li>visse former for medicin, der bruges til behandling af overfølsomhed
(f.eks. terfenadin, astemizol, mizolastin), forstyrrelser i hjerterytmen
(f.eks. disopyramid, procainamid) og depression (f.eks. imipramin,
doxepin, amitriptylin), da disse former for medicin kan påvirke dit
EKG.</li>
<li>visse former for medicin, der bruges til behandling af depression
(bupropion), psykose, hiv- infektion (efavirenz) eller kræft
(cyclophosphamid).</li>
<li>visse former for medicin mod forhøjet kolesterol i blodet (f.eks.
simvastatin, lovastatin, atorvastatin). Disse lægemidler kan give
muskelsmerter og muskelskader. Lægen vil måske ændre dosis af dette
lægemiddel, så længe du tager Ranexa.</li>
<li>visse former for medicin, der hindrer afstødning af et
transplanteret organ (f.eks. tacrolimus, ciclosporin, sirolimus,
everolimus), da lægen måske vil ændre dosis af dette middel, så længe du
tager Ranexa.</li>
</ul>
<p>Fortæl det altid til lægen eller apotekspersonalet, hvis du bruger
anden medicin eller har gjort det for nylig.</p>
<p>Brug af Ranexa sammen med mad og drikke Ranexa kan tages sammen med
eller uden mad. Mens du bliver behandlet med Ranexa, bør du ikke drikke
grapefrugtjuice.</p>
<p>Graviditet Du bør ikke tage Ranexa, hvis du er gravid, medmindre din
læge har anvist det.</p>
<p>Amning Du bør ikke tage Ranexa, hvis du ammer. Spørg din læge til
råds, hvis du ammer.</p>
<p>Hvis du er gravid eller ammer, har mistanke om, at du er gravid,
eller planlægger at blive gravid, skal du spørge din læge til råds, før
du tager dette lægemiddel.</p>
<p>Trafik- og arbejdssikkerhed Det er ikke blevet undersøgt, om Ranexa
påvirker arbejdssikkerheden og evnen til at færdes sikkert i trafikken.
Spørg din læge til råds, før du kører bil eller motorcykel, cykler eller
arbejder med værktøj eller maskiner.</p>
<p>Ranexa kan have bivirkninger såsom svimmelhed (almindeligt), uklart
syn (ikke almindeligt),</p>
<p>forvirring (ikke almindeligt), hallucinationer (ikke almindeligt),
dobbeltsyn (ikke almindeligt) eller koordinationsforstyrrelser
(sjældent), som kan påvirke din evne til at køre eller betjene maskiner.
Hvis du får nogle af disse symptomer, skal du undlade at køre eller
betjene maskiner, indtil du er helt symptomfri.</p>
<p>Ranexa 750 mg depottabletter indeholder azofarvestoffet E 102. Dette
farvestof kan give overfølsomhedsreaktioner.</p>
<p>Ranexa 750 mg depottabletter indeholder lactosemonohydrat. Kontakt
din læge, før du tager dette lægemiddel, hvis din læge har fortalt dig,
at du ikke kan tåle visse sukkerarter.</p>
<p>Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr.
depottablet, dvs. den er i det væsentlige natriumfrit.</p>
 </div>"""   
                    
* section[=].section[+]
  * title =  "3. Sådan skal du tage ranexa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. Sådan skal du tage ranexa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid dette lægemiddel nøjagtigt efter lægens anvisning. Er du i
tvivl, så spørg lægen eller på apoteket.</p>
<p>Tabletterne skal synkes hele sammen med vand. Du må ikke knuse, sutte
på eller tygge tabletterne, og du må heller ikke halvere dem, da dette
kan påvirke måden, hvorpå medicinen frigives i kroppen.</p>
<p>Startdosis for voksne er én 375 mg tablet to gange dagligt. Efter 2-4
uger kan din læge eventuelt sætte dosis op for at opnå den rette
virkning. Den højeste dosis Ranexa er 750 mg to gange dagligt.</p>
<p>Det er vigtigt, at du fortæller det til din læge, hvis du får
bivirkninger såsom svimmelhed, kvalme eller opkastning. Din læge vil
eventuelt sætte din dosis ned eller, hvis dette ikke er tilstrækkeligt,
afbryde behandlingen med Ranexa.</p>
<p>Brug til børn og unge Børn og unge under 18 år bør ikke tage
Ranexa.</p>
<p>Hvis du har taget for mange Ranexa-tabletter Hvis du kommer til at
tage for mange Ranexa-tabletter, eller hvis du tager en højere dosis end
den, din læge har ordineret, er det vigtigt, at du fortæller det til din
læge med det samme. Hvis du ikke kan komme i kontakt med din læge, skal
du tage til den nærmeste skadestue. Medbring alle de resterende
tabletter, tabletbeholderen og æsken, så personalet på hospitalet nemt
kan se, hvad du har taget.</p>
<p>Hvis du har glemt at tage Ranexa Hvis du har glemt at tage en dosis,
skal du tage den, så snart du kommer i tanke om det, medmindre det er
lige ved at være tid til den næste dosis (mindre end 6 timer). Du må
ikke tage en dobbeltdosis som erstatning for den glemte dosis.</p>
 </div>"""         

        
* section[=].section[+]
  * title = "4. Bivirkninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Bivirkninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Ranexa kan som al anden medicin give bivirkninger, men ikke alle får
bivirkninger.</p>
<p>Du skal holde op med at tage Ranexa og kontakte din læge
øjeblikkeligt, hvis du oplever følgende symptomer på angioødem, der er
en sjælden bivirkning, men som kan være alvorlig:</p>
<p> hævelser i ansigt, tunge eller svælg  synkebesvær  nældefeber
eller vejrtrækningsbesvær</p>
<p>Fortæl din læge, hvis du oplever almindelige bivirkninger såsom
svimmelhed, kvalme eller opkastning.</p>
<p>Din læge vil eventuelt sætte din dosis ned eller afbryde behandlingen
med Ranexa.</p>
<p>Andre bivirkninger, som du kan opleve, er:</p>
<p>Almindelige bivirkninger (forekommer hos 1 til 10 brugere ud af 100)
er:<br />
Forstoppelse Svimmelhed Hovedpine Kvalme og opkastning Kraftløshed og
svaghed</p>
<p>Ikke almindelige bivirkninger (forekommer hos 1 til 10 brugere ud af
1.000) er:<br />
Føleforstyrrelser Angst, søvnbesvær, forvirring, hallucinationer Uklart
syn, synsforstyrrelser Ændringer i føle- eller smagssansen, rystelser,
træthed, følelse af ugidelighed, søvnighed eller døsighed,
besvimelsesfornemmelse eller besvimelse, svimmelhed, når man rejser sig
op Mørk urin, blod i urinen, vandladningsbesvær Dehydrering
Åndedrætsbesvær, hoste, næseblødning Dobbeltsyn Overdreven sveden, kløe
Følelse af at være hævet eller oppustet Hedeture, lavt blodtryk<br />
Forhøjet kreatinin- eller urinstofindhold i blodet, forhøjet antal
blodplader eller hvide blodlegemer, ændringer i ekg-kurve Hævelse i led,
smerter i arme og ben Appetitløshed og/eller vægttab Muskelkramper,
muskelsvaghed Ringen for ørerne og/eller følelse af at verden drejer
rundt Mavepine eller ubehag i maven, let mave-tarm-ubehag efter
måltiderne, tørhed i munden eller luft i maven.</p>
<p>Sjældne bivirkninger (forekommer hos 1 til 10 brugere ud af 10.000)
er: Vandladningsbesvær Unormale laboratorieværdier for levertal Akut
nyresvigt Ændringer i lugtesansen, følelsesløshed i munden eller
læberne, nedsat hørelse Koldsved, udslæt Koordinationsforstyrrelser Fald
i blodtrykket, når man rejser sig op Fald i eller tab af bevidsthed
Desorientering Kuldefølelse i hænder og ben Nældefeber,
overfølsomhedsreaktion i huden Impotens<br />
Gangbesvær på grund af balanceforstyrrelser Betændelse i bugspytkirtlen
eller i tarmen,<br />
Hukommelsestab Sammensnøring af strube Lavt natriumindhold i blodet
(hyponatriæmi), hvilket kan medføre træthed og forvirring,
muskeltrækinger, kramper og koma</p>
<p>Ikke kendte bivirkninger (hyppigheden kan ikke estimeres ud fra de
tilgængelige data) er: Myoklonus</p>
<p>Indberetning af bivirkninger</p>
<p>Hvis du oplever bivirkninger, bør du tale med din læge eller
apoteket. Dette gælder også mulige bivirkninger, som ikke er medtaget i
denne indlægsseddel. Du pårørende kan også indberette bivirkninger
direkte til Sundhedsstyrelsen via det nationale rapporteringssystem
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe
med at fremskaffe mere information om sikkerheden af dette
lægemiddel.</p>
 </div>"""      
        
* section[=].section[+]
  * title = "5. Opbevaring"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. Opbevaring"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn.</p>
<p>Brug ikke dette lægemiddel efter den udløbsdato, der står på hver
blisterstrip og uden på æsken og flasken efter EXP.</p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende
opbevaringen.</p>
<p>Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Af
hensyn til miljøet må du ikke smide medicinrester i afløbet, toilettet
eller skraldespanden.</p>
 </div>"""      
        
        
* section[=].section[+]
  * title = "6. Pakningsstørrelser og yderligere oplysninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Pakningsstørrelser og yderligere oplysninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Ranexa indeholder: Aktivt stof: ranolazin. Hver tablet indeholder 375
mg, 500 mg eller 750 mg ranolazin.</p>
<p>Øvrige indholdsstoffer: hypromellose, magnesiumstearat,
methacrylsyre-ethylacrylatcopolymer, mikrokrystallinsk cellulose,
natriumhydroxid, titaniumdioxid og carnaubavoks.</p>
<p>Afhængig af tablettens styrke indeholder overtrækket også: 375 mg
tablet: makrogol, polysorbat 80, Blå 2/Indigocarmin aluminium lake (E
132) 500 mg tablet: makrogoltalcum, polyvinylalkohol, delvist
hydrolyseret, jernoxid, gul (E172), jernoxid, rød (E172) 750 mg tablet:
glyceroltriacetat, lactosemonohydrat, Blå 1/Brilliant Blue FCF aluminium
lake (E 133) og Gul 5/Tartrazin aluminium lake (E 102)</p>
<p>Ranexas udseende og pakningsstørrelse Ranexa depottabletter er ovale.
375 mg-tabletterne er lyseblå og præget med 375 på den ene side. 500
mg-tabletterne er lys orange og præget med 500 på den ene side. 750
mg-tabletterne er lysegrønne og præget med 750 på den ene side.</p>
<p>Ranexa fås i æsker med 30, 60 eller 100 tabletter i blisterstrips
eller 60 tabletter i plasticflasker. Ikke alle pakningsstørrelser er
nødvendigvis markedsført.</p>
<p>Indehaveren af markedsføringstilladelsen Menarini International
Operations Luxembourg S.A. 1, Avenue de la Gare, L-1611 Luxembourg,
Luxembourg</p>
<p>Fremstiller Menarini - Von Heyden GmbH Leipziger Straβe 7-01097
Dresden<br />
Tyskland</p>
<p>eller</p>
<p>Berlin-Chemie AG</p>
<p>Glienicker Weg 12489 Berlin Tyskland</p>
<p>Hvis du vil have yderligere oplysninger om Ranexa, skal du henvende
dig til den lokale repræsentant:</p>
<p>België/Belgique/Belgien Menarini Benelux NV/SA Tél/Tel: + 32 (0)2 721
4Lietuva UAB “BERLIN-CHEMIE MENARINI BALTIC" Tel: +370 52 691<br />
България “Берлин-Хеми/А. Менарини България" ЕООД<br />
тел.: +359 2 454 0Luxembourg/Luxemburg Menarini Benelux NV/SA Tél/Tel: +
32 (0)2 721 4 Česká republika Berlin-Chemie/A.Menarini Ceska republika
s.r.o. Tel: +420 267 199<br />
Magyarország Berlin-Chemie/A. Menarini Kft. Tel.: +36 17997 Danmark
Menarini International Operations Luxembourg S.A. Tel: +352 264 Malta
Menarini International Operations Luxembourg S.A. Tel: +352 264
Deutschland Berlin-Chemie AG Tel: +49 (0) 30 67Nederland Menarini
Benelux NV/SA Tel: +32 (0)2 721 4Eesti OÜ Berlin-Chemie Menarini Eesti
Tel: +372 667 5Norge Menarini International Operations Luxembourg S.A.
Tlf: +352 264Ελλάδα MENARINI HELLAS AE Τηλ: +30 210 8316111-Österreich
A. Menarini Pharma GmbH. Tel: +43 1 879 95 85-0 España Laboratorios
Menarini S.A. Tel: +34-93 462 88 Polska Berlin-Chemie/Menarini Polska
Sp. z o.o. Tel.: +48 22 566 21 France MENARINI France Tél: +33 (0)1 45
60 77 Portugal A. Menarini Portugal - Farmacêutica, S.A. Tel: +351 210
935 Hrvatska Berlin-Chemie Menarini Hrvatska d.o.o. Tel: + 385 1 4821
România Berlin-Chemie A. Menarini S.R.L. Tel: +40 211 232 34<br />
Ireland A. Menarini Pharmaceuticals Ltd Tel: +353 1 284 6Slovenija
Berlin-Chemie / A. Menarini Distribution Ljubljana d.o.o.Tel: +386 01
300 2Ísland Menarini International Operations Luxembourg S.A. Sími: +352
264Slovenská republika Berlin-Chemie / A. Menarini Distribution Slovakia
s.r.o Tel: +421 2 544 30 Italia A. Menarini Industrie Farmaceutiche
Riunite s.r.l. Tel: +39-055 56 Suomi/Finland Berlin-Chemie/A.Menarini
Suomi OY Puh/Tel: +358 403 000 Κύπρος MENARINI HELLAS AE Τηλ: +30 210
8316111-Sverige Menarini International Operations Luxembourg S.A. Tel:
+352 264Latvija SIA Berlin-Chemie/Menarini Baltic Tel: +371 67103United
Kingdom (Northern Ireland) A. Menarini Farmaceutica Internazionale
S.R.L. Tel: +44 (0)1628 856</p>
<p>Denne indlægsseddel blev senest ændret {MM/ÅÅÅÅ}.</p>
<p>Du kan finde yderligere information om Ranexa på Det Europæiske
Lægemiddelagenturs hjemmeside <a
href="http://www.ema.europa.eu">http://www.ema.europa.eu</a>.</p>
 </div>"""      





                    
Instance: bundlepackageleaflet-en-2128cb95d4d26d25d7fa2c3944c0ae92
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for ranexa Package Leaflet for language en"
Description: "ePI document Bundle for ranexa Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-2128cb95d4d26d25d7fa2c3944c0ae92"
* entry[0].resource = composition-en-2128cb95d4d26d25d7fa2c3944c0ae92

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp2128cb95d4d26d25d7fa2c3944c0ae92"
* entry[=].resource = mp2128cb95d4d26d25d7fa2c3944c0ae92
                            
                    
Instance: bundlepackageleaflet-da-2128cb95d4d26d25d7fa2c3944c0ae92
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for ranexa Package Leaflet for language da"
Description: "ePI document Bundle for ranexa Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-2128cb95d4d26d25d7fa2c3944c0ae92"
* entry[0].resource = composition-da-2128cb95d4d26d25d7fa2c3944c0ae92

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp2128cb95d4d26d25d7fa2c3944c0ae92"
* entry[=].resource = mp2128cb95d4d26d25d7fa2c3944c0ae92
                            
                    



Instance: mp2128cb95d4d26d25d7fa2c3944c0ae92
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Ranexa 375 mg prolonged-release tablets"
Description: "Ranexa 375 mg prolonged-release tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/08/462/001  60 tablets in blister pack"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Ranexa 375 mg prolonged-release tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 2128cb95d4d26d25d7fa2c3944c0ae92ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "ranexa"

* status = #current
* mode = #working

* title = "List of all ePIs associated with ranexa"

* subject = Reference(mp2128cb95d4d26d25d7fa2c3944c0ae92)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#ranexa "ranexa"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-2128cb95d4d26d25d7fa2c3944c0ae92) // ranexa en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-2128cb95d4d26d25d7fa2c3944c0ae92) // ranexa da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-2128cb95d4d26d25d7fa2c3944c0ae92
InstanceOf: List
Description: "ePI document List for ranexa Package Leaflets"

* insert 2128cb95d4d26d25d7fa2c3944c0ae92ListRuleset
    